Leticia Gonzalez, MD
Family Medicine · Bronx, NYNPI 1174616577
Payments from drug & device makers
Across 290 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- GSK$708
- AstraZeneca$422
- Astellas Pharma US Inc$402
- Avanir Pharmaceuticals, Inc.$355
- Novartis$318
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,92497%
- Education$1603%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 82 | $1,509 |
| GSK | 29 | $708 |
| AstraZeneca | 23 | $422 |
| Astellas Pharma US Inc | 14 | $402 |
| Avanir Pharmaceuticals, Inc. | 16 | $355 |
| Novartis | 20 | $318 |
| Gilead | 8 | $272 |
| Lilly USA, LLC | 14 | $233 |
| AbbVie | 11 | $220 |
| Intra-sana Laboratories | 4 | $219 |
| Pfizer | 11 | $180 |
| Amarin Pharma, Inc. | 8 | $161 |
| Boehringer Ingelheim | 5 | $107 |
| Sanofi-aventis U.S. LLC | 6 | $106 |
| Bayer | 4 | $89 |
| Otsuka America Pharmaceutical, Inc. | 3 | $83 |
| Johnson & Johnson | 4 | $82 |
| Mallinckrodt Hospital Products Inc. | 2 | $64 |
| Abbott | 3 | $57 |
| Mallinckrodt Enterprises LLC | 2 | $57 |
| Boston Scientific | 1 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Dexcom, Inc. | 2 | $46 |
| Seqirus USA Inc | 2 | $38 |
| Merck | 2 | $35 |
| Amgen | 2 | $29 |
| Genentech USA, Inc. | 1 | $24 |
| Bausch Health US, LLC | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Cumberland Pharmaceuticals, Inc. | 1 | $21 |
| Smith+Nephew | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Lundbeck LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reltone 200 Mg$133
- GLYCATE$133
- Reltone 400 Mg$133
- AREXVY$125
- Truvada$125
How this compares
$6,084 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 148 | $191,174 |
| OzempicSemaglutide | 132 | $161,324 |
| EliquisApixaban | 161 | $108,786 |
| JardianceEmpagliflozin | 120 | $74,805 |
| JanuviaSitagliptin Phosphate | 39 | $46,123 |
| FarxigaDapagliflozin Propanediol | 55 | $42,597 |
| Bydureon BciseExenatide Microspheres | 29 | $26,726 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $26,603 |
| EntrestoSacubitril/Valsartan | 59 | $19,885 |
| XareltoRivaroxaban | 39 | $17,177 |
| Sevelamer Carbonate | 33 | $13,513 |
| LinzessLinaclotide | 21 | $11,679 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 40 | $9,405 |
| VascepaIcosapent Ethyl | 14 | $8,964 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $8,387 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $233 | $191,174148 claims |
| Novo NordiskOzempic | $1,509 | $161,324132 claims |
| PfizerEliquis, Abrysvo | $180 | $112,494172 claims |
| Boehringer IngelheimJardiance, Tradjenta | $107 | $80,740138 claims |
| AstraZenecaFarxiga, Lokelma, Brilinta | $422 | $53,12195 claims |
| MerckJanuvia | $35 | $46,12339 claims |
| GSKBreo Ellipta | $708 | $26,60361 claims |
| NovartisEntresto | $318 | $19,88559 claims |
| Johnson & JohnsonXarelto | $82 | $17,17739 claims |
| AbbVieLinzess, Synthroid | $220 | $13,85556 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Bronx
- Eugene SchiffBronx$184K
- Hui-Li HuangBronx$41K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.